These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 28819882)

  • 1. Novel Immunotherapies for Multiple Myeloma.
    D'Agostino M; Boccadoro M; Smith EL
    Curr Hematol Malig Rep; 2017 Aug; 12(4):344-357. PubMed ID: 28819882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapeutic Approaches for Multiple Myeloma: Where Are We Now?
    Htut M
    Curr Hematol Malig Rep; 2019 Feb; 14(1):1-10. PubMed ID: 30666505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
    Podar K; Jager D
    Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting BCMA in Multiple Myeloma.
    Tan CR; Shah UA
    Curr Hematol Malig Rep; 2021 Oct; 16(5):367-383. PubMed ID: 34432234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune Therapies in Multiple Myeloma.
    Kumar SK; Anderson KC
    Clin Cancer Res; 2016 Nov; 22(22):5453-5460. PubMed ID: 28151713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to Train Your T Cells: Overcoming Immune Dysfunction in Multiple Myeloma.
    Cohen AD; Raje N; Fowler JA; Mezzi K; Scott EC; Dhodapkar MV
    Clin Cancer Res; 2020 Apr; 26(7):1541-1554. PubMed ID: 31672768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Editorial: Multiple Myeloma Immunotherapies.
    Podar K
    Curr Cancer Drug Targets; 2017; 17(9):768. PubMed ID: 29117857
    [No Abstract]   [Full Text] [Related]  

  • 10. CD38 as an immunotherapeutic target in multiple myeloma.
    Bonello F; D'Agostino M; Moscvin M; Cerrato C; Boccadoro M; Gay F
    Expert Opin Biol Ther; 2018 Dec; 18(12):1209-1221. PubMed ID: 30394809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for the treatment of multiple myeloma.
    Jung SH; Lee HJ; Vo MC; Kim HJ; Lee JJ
    Crit Rev Oncol Hematol; 2017 Mar; 111():87-93. PubMed ID: 28259300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of Novel Immunotherapies for Multiple Myeloma.
    Al-Hujaily EM; Oldham RA; Hari P; Medin JA
    Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27618026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B cell maturation antigen (BCMA)-based immunotherapy for multiple myeloma.
    Tai YT; Anderson KC
    Expert Opin Biol Ther; 2019 Nov; 19(11):1143-1156. PubMed ID: 31277554
    [No Abstract]   [Full Text] [Related]  

  • 14. The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies.
    Hoyos V; Borrello I
    Blood; 2016 Sep; 128(13):1679-87. PubMed ID: 27506540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B-cell maturation antigen directed monoclonal antibody therapies for multiple myeloma.
    Eckhert E; Hewitt R; Liedtke M
    Immunotherapy; 2019 Jun; 11(9):801-811. PubMed ID: 31094254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunopathogenesis and immunotherapy of multiple myeloma.
    Tamura H
    Int J Hematol; 2018 Mar; 107(3):278-285. PubMed ID: 29368256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Novel therapies for multiple myeloma].
    Ri M
    Rinsho Ketsueki; 2024; 65(6):547-557. PubMed ID: 38960655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies as an addition to current myeloma therapy strategies.
    Jullien M; Touzeau C; Moreau P
    Expert Rev Anticancer Ther; 2021 Jan; 21(1):33-43. PubMed ID: 33052750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The development of potential antibody-based therapies for myeloma.
    Sherbenou DW; Behrens CR; Su Y; Wolf JL; Martin TG; Liu B
    Blood Rev; 2015 Mar; 29(2):81-91. PubMed ID: 25294123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CAR T cell therapies for patients with multiple myeloma.
    Mikkilineni L; Kochenderfer JN
    Nat Rev Clin Oncol; 2021 Feb; 18(2):71-84. PubMed ID: 32978608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.